“Burkitt-like lymphoma with 11q aberration” is a new provisional entity in the latest revision of lymphoma's World Health Organization classification described as carrying the specific 11q-gain/loss aberration and lacking MYC rearrangement. Morphologically, phenotypically and by gene and microRNA expression profiling these lymphomas resemble Burkitt lymphoma. The 11q-gain/loss was also found in post-transplant patients with molecular Burkitt lymphoma signature without MYC rearrangement. Recent reports describe aggressive lymphomas with coexistence of 11q-gain/loss and MYC rearrangement. In this report we describe post-transplant Burkitt-like lymphoma with 11q aberration and MYC amplification. Genetic studies were conducted at two time points: before therapy and during progression. In both cytogenetic examinations, peculiar 11q-gain/loss was detected. Percentage of cells carrying MYC amplification increased from 2% at initial diagnosis to 97% during progression. The MYC amplification can functionally correspond to MYC translocation and to MYC overexpression. The presence of MYC amplification seems to increase the aggressiveness of the reported disease course, so even a small clone with this change should be indicated in cytogenetic result.

“具有11q畸变的伯基特样淋巴瘤”是世界卫生组织最新修订的淋巴瘤分类中的一个新的临时实体，该分类被描述为具有特定的11q增益/丢失畸变且缺乏MYC重排。从形态上，表型上以及通过基因和微小RNA表达谱分析这些淋巴瘤类似于伯基特淋巴瘤。在具有分子Burkitt淋巴瘤特征但无MYC重排的移植后患者中也发现了11q增益/损失。最近的报道描述了侵袭性淋巴瘤与11q增益/丢失和MYC重排并存。在本报告中，我们描述了11q畸变和MYC的Burkitt样淋巴瘤移植后放大。遗传研究是在两个时间点进行的：治疗前和进展期间。在两种细胞遗传学检查中，均检测到了特殊的11q增益/丢失。携带MYC扩增的细胞百分比从最初诊断时的2％增加到进展期间的97％。该MYC放大可以在功能上与MYC易位以及MYC过表达。MYC扩增的存在似乎增加了所报道的疾病进程的侵袭性，因此即使在细胞遗传学结果中也应指出具有这种改变的小克隆。